Axonal Guillain‐Barre syndrome associated with SARS‐CoV‐2 infection in a child

Akçay, Nihal; Menentoğlu, Mehmet Emin; Bektaş, Gonca; Şevketoğlu, Esra

The relation between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and demyelinating Guillain‐Barre syndrome (GBS) has been defined. We aim to report the clinical features of a child with axonal GBS associated with SARS‐CoV‐2. A 6‐year‐old male presented with symmetric ascending paralysis progressed over a 4‐day course and 2 days of fever. He had bilateral lower and upper limb flaccid weakness of 1/5 with absent deep tendon reflexes. He had severe respiratory muscle weakness requiring invasive mechanical ventilation. On admission, SARS‐CoV‐2 returned as positive by real‐time polymerase chain reaction on a nasopharyngeal swab. Cerebrospinal fluid analysis showed elevated protein without pleocytosis. He was diagnosed with GBS associated with SARS‐CoV‐2 infection. The nerve conduction study was suggestive of acute motor axonal neuropathy. Ten consecutive therapeutic plasma exchange sessions with 5% albumin replacement followed by four sessions on alternate days were performed. On Day 12, methylprednisolone (30 mg/kg/day for 5 days) was given. On Day 18, intravenous immunoglobulin (2 g/kg/day) was given and repeated 14 days after due to severe motor weakness. On Day 60, he was discharged from the hospital with weakness of neck flexor and extensor muscles of 3/5 and the upper limbs and the lower limbs of 2/5 on home‐ventilation. Our patient is considered to be the youngest patient presenting with a possible para‐infectious association between axonal GBS and SARS‐CoV‐2 infection. The disease course was severe with a rapid progression, an earlier peak, and prolonged duration in weakness as expected in axonal GBS.